Baseline co-occurring mutations by functional category and clinical response status (n = 33*). RTK pathway mutations were not observed in patients achieving CR/CRh responses (P = .01 by Fisher exact test). *One patient enrolled in dose-escalation phase was positive for the IDH1-D54N mutation by local testing and was not positive for the IDH1-R132 mutation by the companion diagnostic test; this patient was therefore excluded from the efficacy analyses. + indicates patients with treatment duration of >32 months. Red horizontal bars indicate IDH1 mutation clearance. IDH-MC, IDH-mutation clearance.